On-Demand Presentations and Slides

Optimizing Personalized Care of Patients With Colorectal Cancer

Release date 26-11-2020

Expiration date 26-11-2021

Advances in the molecular characterization of colorectal cancer (CRC) and an increasing number of personalized treatment approaches, including targeted therapy and immunotherapy, are adding to the complexity of metastatic CRC (mCRC) management. View expert faculty presentations, panel discussions, and downloadable slides from the recent live webinar, ‘Optimizing Personalized Care of Patients with Colorectal Cancer’ which was part of the 2020 Conference of Fudan Zhongshan Cancer Center, and stay up-to-date with current and emerging biomarkers, evolving tools for better patient selection, and new strategies for optimizing personalized treatment of mCRC.

Faculty

Tianshu Liu, MD, PhD

Tianshu Liu, MD, PhD | Chair

Department of Medical Oncology

Zhongshan Hospital, Fudan University

Shanghai, China

Professor Tianshu Liu is Chief Physician and Director of Oncology at Zhongshan Hospital, Fudan University, Shanghai. She has been Director of the Department of Oncology at Zhongshan Hospital since 2013, and is a certified tutor for Masters and Doctoral degrees. Dr Liu is a dedicated clinical researcher, primarily focused on biomarkers and new treatment strategies for advanced colorectal and gastric cancer. Since 2012, she has served as the PI in Zhongshan Hospital for more than 70 clinical trials, including many international Phase I-III trials; the findings of these trials have been published in prestigious journals including J Clin Oncol, JAMA, and Lancet Oncol. She has also been the corresponding author on more than 50 scientific papers over the last 5 years. Professor Liu has received several awards including the Shanghai Medical Scientific Award in 2020 for her work “The Establishment and Promotion of the Standardized System of Whole-process Management of Colorectal Cancer”.

Dirk Arnold, MD, PhD

Dirk Arnold, MD, PhD

Department of Oncology and Hematology

Asklepios Tumorzentrum Hamburg

Hamburg, Germany

Dirk Arnold, MD, PhD is a Medical Oncologist. He was appointed as Professor of Internal Medicine/Oncology at the University of Hamburg, Germany in 2010, where he currently serves as Medical Director of the Asklepios Tumor Centre. Professor Arnold’s major fields of scientific interest are the treatment of gastrointestinal and genitourinary cancers, focusing on molecular-targeted therapies, immunotherapy, multimodal treatment strategies, and early drug development. He serves as Chairman of the Colorectal Cancer Study Group of the German Arbeitsgemeinschaft Internistische Onkologie (AIO). He is a member of the Colorectal Cancer Task Force and the Board of the Gastrointestinal Cancer Study Group of the EORTC. Professor Arnold is also a key member of several German and international cancer societies, including ASCO and ESMO, where he serves as faculty and council member, and section editor of the Guidelines Committee for Gastrointestinal Cancers.  

Junjie Peng, MD, PhD

Junjie Peng, MD, PhD

Department of Colorectal Surgery

Fudan University Shanghai Cancer Center

Shanghai, China

Junjie Peng, MD, PhD is a Surgical Oncologist and Associate Professor at the Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai. Dr Peng obtained his medical degree in 2009 from Fudan University, Shanghai. He received his surgical training at Fudan University Shanghai Cancer Center and at the University of California, San Francisco, US. Dr Peng is dedicated to the management of patients with colorectal cancer and is also involved in clinical and cancer biomarker research. He is first author and co-author of many articles published in high-profile scientific journals.

Yiyi Yu, MD

Yiyi Yu, MD

Department of Medical Oncology

Zhongshan Hospital, Fudan University

Shanghai, China

Dr Yiyi Yu, MD is an Associate Chief Physician in the Department of Medical Oncology at Zhongshan Hospital Fudan University, Shanghai. As a medical oncologist and cancer researcher, her focus has been to characterize the genomic alterations underlying colorectal and gastric cancer, especially the mechanisms of anti-EGFR antibody resistance. She obtained a National Natural Science Fund in this field. She has participated in more than 80 clinical studies and is an author on several pivotal publications. Dr Yu has actively participated in many oncology conferences, including the American Society of Clinical Oncology (ASCO), the Chinese Society of Clinical Oncology (CSCO), the European Society for Medical Oncology (ESMO), and ASCO-GI. Dr Yu is devoted to the study of colorectal and gastric cancer, and through translational research, she aims to make major inroads in these diseases.

Clara Montagut, MD, PhD

Clara Montagut, MD, PhD

Department of Medical Oncology

Hospital del Mar

Barcelona, Spain

Dr Clara Montagut is Head of the Gastrointestinal Cancer Unit in the Medical Oncology Department at the Hospital del Mar, Barcelona, Spain, and is currently working for a year at the Memorial Sloan Kettering Cancer Center in New York, US, on liquid biopsy and immunotherapy in colon cancer. She is also Professor at the Pompeu Fabra University, Barcelona. Dr Montagut received her medical degree from the Universitat Autònoma de Barcelona, Spain, trained in medical oncology at the Hospital Clínic de Barcelona, and completed her training at the Massachusetts General Hospital Cancer Center in Boston, US. In 2008, she was awarded her doctoral thesis with distinction cum laude from the Universitat de Barcelona. Dr Montagut has led and participated in many clinical trials in GI cancer and has published in several prestigious journals, including Nat Med. She is a member of the Spanish Association of Medical Oncology, Spanish Group of Digestive Tumors, Spanish Melanoma Group, ESMO, and ASCO.

Xicheng Wang, MD, PhD

Xicheng Wang, MD, PhD

Department of Gastrointestinal Oncology

Peking University Cancer Hospital & Institute

Beijing, China

Dr Xicheng Wang is an Associate Professor of Medical Oncology at Peking University Cancer Hospital in Peking, and specializes in gastrointestinal cancers. Dr Wang received his medical degree from Peking University Health Science Center in 2001, and subsequently studied at the Johns Hopkins University, Baltimore, US, where he was awarded a PhD in Physiology in 2006. He completed his residency and fellowship training at Peking University Cancer Hospital in 2012. His main research interests include precision medicine in colorectal cancer and hereditary gastrointestinal cancers.

Ian Chau, MD, FRCP

Ian Chau, MD, FRCP

Gastrointestinal and Lymphoma Units

The Royal Marsden Hospital

London, United Kingdom

Dr Ian Chau is Consultant Medical Oncologist in the GI and Lymphoma Units at Royal Marsden Hospital and Reader at the Institute of Cancer Research, London & Surrey, UK. He is Chief or PI of multiple Phase I-III clinical trials evaluating new treatment strategies and agents in various cancer signalling pathways. He serves or has served on ASCO and ESMO Steering, Scientific Program and Education Committees, and UK National Cancer Research Institute (NCRI) CRC and Pancreatic Cancer Clinical Study Groups. He is on the Trial Management Groups and Trial Steering Groups of multiple Phase II–III GI cancer and lymphoma trials. He serves or has served on the UK NICE Clinical Guideline Development Group for Non-Hodgkin’s Lymphoma, ASCO Expert Panel for the Management of Immunotherapy Toxicities Guideline, and ESMO Clinical Practice Guidelines for Hepatocellular Carcinoma panel. He is the recipient of several awards and fellowships and has many publications in leading oncology/biomedical journals.

  • Advancing precision medicine in colorectal cancer: The role of NGS in molecular profiling | Dirk Arnold, MD, PhD

  • Commentary – Clinical utility of liquid biopsy in patients with CRC  | Junjie Peng, MD, PhD

  • Questions from the audience and faculty panel discussion

  • Clinical case – RAS wild-type mCRC: Consideration of treatment strategies across the disease continuum  | Yiyi Yu, MD

  • Commentary – When to consider anti-EGFR rechallenge  | Clara Montagut, MD, PhD

  • Clinical case – MSI-H mCRC: Treatment sequencing | Xicheng Wang, MD, PhD

  • Commentary – Why immunotherapy in mCRC only works in MSI-H cancer | Ian Chau, MD, FRCP

  • Questions from the audience and faculty panel discussion
This educational activity is designed specifically for medical oncologists, gastroenterologists, surgical oncologists, and other healthcare professionals involved in the management of colorectal cancer.
Upon completion of this educational activity, participants should be able to:

 

  • Evaluate current and emerging biomarkers to guide precision medicine in mCRC, and explain the role of NGS for molecular profiling
  • Assess potential use of liquid biopsy in CRC, including monitoring for anti-EGFR resistance and identifying patients for treatment rechallenge
  • Select optimal treatment approaches for patients with RAS wild-type and MSI-H mCRC, first-line and beyond

 

Provided by ACE Oncology.
This educational activity is supported by an independent grant from the Healthcare business of Merck KGaA, Darmstadt, Germany.
This activity was part of the 2020 Conference of Fudan Zhongshan Cancer Center.
This on-demand webcast includes content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve knowledge, competence, and performance of clinicians in order to improve patient care.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

 

Dirk Arnold has served as an advisor or consultant for BMS, Lilly, Sanofi, Roche, MSD, and AstraZeneca. He has served as a speaker or a member of a speakers bureau for Merck Serono, Tesaro, and Amgen. Any unlabeled/unapproved uses of drugs or products referenced in his presentation will be specified.

 

Junjie Peng has no financial relationships to disclose. Any unlabeled/unapproved uses of drugs or products referenced in his presentation will be specified.

 

Yiyi Yu has served as a speaker or a member of a speakers bureau for Roche, Merck, BMS, AstraZeneca, HengRui, Sanofi-Aventis, and Pfizer. Any unlabeled/unapproved uses of drugs or products referenced in her presentation will be specified.

 

Clara Montagut has served as an advisor or consultant for Amgen, Roche, Merck Serono, Sanofi, and Biocartis. She has served as a speaker or a member of a speakers bureau for Merck Serono, Roche, Biocartis, and Amgen. Prof Montagut has received grants for clinical research from Symphogen. Any unlabeled/unapproved uses of drugs or products referenced in her presentation will be specified.

 

Xicheng Wang has no financial relationships to disclose. Any unlabeled/unapproved uses of drugs or products referenced in his presentation will be specified.

 

Ian Chau has served as an advisor or consultant for Eli-Lilly, Bristol Myers Squibb, MSD, Bayer, Roche, Merck Serono, Five Prime Therapeutics, AstraZeneca, Oncologie International, Pierre Fabre, and Boehringer Ingelheim. Prof Chau has received grants for clinical research from Eli-Lilly, and Janssen-Cilag. Any unlabeled/unapproved uses of drugs or products referenced in his presentation will be specified.

 

The employees of ACE Oncology have disclosed no relevant financial relationships.

 

ACE Oncology require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COIs are thoroughly vetted and resolved according to ACE Oncology’s policy. ACE Oncology is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

Start Activity